The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies
Clinical trial NCT07020260 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07020260
- Sponsor
- Princess Maxima Center for Pediatric Oncology
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-01
- Primary completion
- 2027-09-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.